Introduction
Cardiovascular (CV) disease (CVD) is the main cause of worldwide premature mortality.
Coronary heart disease (CHD) and stroke ranked first and third, respectively, as the leading global causes of disability-adjusted years according to the global burden of disease estimates for 2010 1 . Furthermore, the projections of mortality from CVD for 2030 are dismal 2,3 and underline the need for preventive strategies as a public health priority. In this context, a highquality diet and a healthy lifestyle at middle age are the most important factors for CVD prevention 3-7 . Consequently, the diet-heart hypothesis has been a long-standing tenet in CVD prevention and nutritional epidemiology during the last 50 years 7-8 . Recently, the relevance of overall high-quality food patterns, rather than the focus on single nutrients and foods, has emerged as a powerful paradigm to address the inherent complexity of dietary exposures and to assess their potential CVD preventive effects. Food patterns can be described as the amounts, proportions, combinations or varieties for the consumption of different foods and beverages and the frequency with which they are usually consumed. This approach allows the assessment of synergistic interactions and cumulative effects among different foods and nutrients, preempts confounding by alternative dietary exposures, avoids some problems of co-linearity between foods or nutrients and thus provides a strong methodological tool in nutritional epidemiology 9-10 . Even though randomized dietary intervention trials are the hallmarks for acquiring knowledge on the effects of diet on CVD, most research in the field of dietary patterns is observational, with some potential for residual confounding and other possible sources of bias. These limitations have been the subject of ample but probably undue criticism 10, 11 .
A weakness of the diet-heart hypothesis is that most of the available experimental research in the field has not used hard clinical outcomes, but only intermediate risk biomarkers. The
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ACCEPTED MANUSCRIPT 5 existence of multiple pathways leading from diet to CVD speaks against the simplistic approach of giving a high value to changes in any single biomarker. Moreover, the induction period can vary for the different pathways in which diverse biomarkers are involved, thus limiting the possibility of assessing multiple biomarker combinations at any time point.
Furthermore, other lesser-known pathways could account for a substantial proportion of clinical CVD events. The most sensible approach, therefore, in order to investigate the dietheart hypothesis is to use hard clinical CVD events as end-points of randomized controlled trials (RCTs). Most feeding trials, however, are usually short term and rarely include clinical end-points such as CVD events or death 11 . The PREDIMED trial was designed to overcome both the problem of the single-nutrient approach and the limitations of assessing only intermediate risk markers. Indeed, the PREDIMED randomized trial used an overall food pattern as the intervention and assessed hard CVD events as end-points 12 providing a high level of scientific evidence.
Scientific evidence of the cardio-metabolic benefits of the Mediterranean diet
The abundant and consistent observational evidence that was available to support the benefits of the Mediterranean diet (MeDiet) and, specifically, of tree nuts and olive oil, on CV health prompted us to choose this traditional dietary model enriched with olive oil or nuts as the intervention 13-44 . Table 1 summarizes the results of meta-analyses and systematic reviews assessing the effects of MeDiet on different cardiometabolic outcomes.
The MeDiet is defined as the traditional dietary pattern found in the early 1960s in Greece, Southern Italy, Spain and other olive-growing countries of the Mediterranean basin. It is a frugal diet that uses generous amounts of olive oil as main culinary fat and has a high
consumption of plant-derived foods (fruit, vegetables, legumes, nuts and seeds, and whole grain cereals); frequent but moderate intake of wine (especially red wine), usually with meals; moderate consumption of seafood and dairy products (especially yogurt and cheese, but not whole milk, butter or cream), poultry and eggs; and low consumption of sweet desserts, red and processed meats. In comparison with other healthy patterns, such as the DASH diet, the healthy US dietary pattern or the Alternative Healthy Eating Index, the consumption of fruit and fish is usually higher in the MeDiet, while the consumption of dairy products tends to be lower. In healthy vegetarian food patterns, meat and seafood are not consumed, but eggs and dairy are most frequently included. Legumes, nuts/seeds, and processed soy are all higher in a healthy vegetarian food pattern than in the healthy U.S.-style or Mediterranean-style patterns.
A considerable scientific advantage of the MeDiet over other healthy dietary patterns was the availability of a previous randomized trial, the Lyon Diet Heart study, conducted in myocardial infarction survivors (i.e., it was a secondary prevention trial). It showed that a MeDiet enriched with alpha-linolenic acid, but not olive oil, provided a strong protection against recurrent CHD 45 .
Our hypothesis when designing the PREDIMED trial was that the MeDiet would be superior to a low-fat diet for primary CVD prevention. This hypothesis had never been tested previously using a RCT design.
Design and methods of the PREDIMED study
The PREDIMED study was a primary prevention trial which tested the long-term effects of We selected participants from >200 primary care facilities affiliated with 11 recruiting sites.
All participants were at high risk for CVD, but had no history of previous CVD episodes at enrolment. Criteria for recruitment were the presence of either type 2 diabetes mellitus An event adjudication committee, whose members were blinded to group allocation, was responsible for event ascertainment. All participants provided written informed consent and the protocol was approved by the Institutional Review Boards of all participating centers.
Main results of the PREDIMED trial
We randomized 7447 participants into the three PREDIMED intervention groups. The groups were well-balanced with respect to their baseline characteristics and pharmacologic treatments. Though small, between-group differences in some baseline characteristics were observed, but they were not clinically meaningful. Furthermore, we adjusted all risk estimates for these variables. The mean age of participants was 67 years, 57% were women and the mean body mass index was 30 kg/m 2 . The baseline prevalence of diabetes was nearly 50% and the prevalence of DLP and HTN was higher than 70% and 80%, respectively.
Compliance with the intervention in the two MeDiet groups was adequate 48 . Our tracking of objective biomarkers in random participant subsamples also indicated compliance with the intended dietary intervention. However, the achieved absolute difference in adherence to the MeDiet (according to the 14-item screener) between the intervention group and the control group was modest, amounting to a maintained difference of 2 points out of 14.
There were no between-group differences in physical activity during the study. No dietrelated adverse effects occurred.
We assessed the effect of baseline adherence to the 14-point score with respect to the subsequent incidence of the primary CVD end-point during follow-up 49 . As shown in Figure   1 , the effect was remarkable. The multivariable-adjusted hazard ratio for participants with a baseline 14-item screener in the 2 nd -3 rd quintile who scored between 8-9 points was 0. Table 3 shows the number of hard clinical CVD events that could be prevented in a hypothetical cohort of 1,000 persons undergoing the nutritional intervention with the MeDiet used in the PREDIMED trial. These results suggest that even a modest intervention with the MeDiet has the potential to account for a sizable reduction in the number of clinical events in a relatively short period of time. 
Number of events hypothetically prevented with the Mediterranean diet

Observational studies and trials in the context of the PREDIMED trial
Mechanisms of protection by the Mediterranean diet
Genomics and the Mediterranean diet
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ACCEPTED MANUSCRIPT 13 We investigated whether the effects of the MeDiet or its components might differ depending on genetic variants. We found several gene-diet interactions in determining both intermediate concentrations and lipids than CC+CT individuals but when adherence was high, these differences were not apparent. Moreover, TT subjects had a higher stroke incidence in the control group compared with CC, whereas the dietary intervention with MedDiet was associated with reduced stroke incidence in TT homozygotes but not CC homozygotes 108 .
Both genetic and epigenetic effects on microRNA target site polymorphisms were also analyzed. A gain-of-function microRNA-410 target site polymorphism (rs13702T>C) in the lipoprotein lipase gene, interacted with the MedDiet intervention in the association with triglyceride levels and stroke incidence 110 . The interplay between genetic and epigenetic factors may contribute to better understand some biological mechanisms underlying CVD progression. Overall these results highlight the relevance of the multi-level omics approaches to a more comprehensive investigation of the mechanisms accounting for the MedDiet protective effects.
Conclusions
The findings from the PREDIMED trial, the Lyon Diet-Heart trial, and many large prospective cohorts are fully consistent. These large observational and experimental studies are also supported by mechanistic investigations aimed to assess classical and emergent CVD risk factors and pathophysiological pathways. Anti-inflammatory effects and reduced oxidative stress are very likely explanations for the protection observed in the PREDIMED trial. Taken together, these research findings converge, demonstrating that the traditional MeDiet offers an affordable, attractive, and easily achievable protection against CVD.
Importantly, these findings suggest that an overall dietary pattern that is rich in highunsaturated fat from natural vegetable sources is preferable for CV health than a low-fat diet.
In addition, the MeDiet has been shown to effectively control the residual risk observed after standard pharmacologic treatment of DLP anomalies and HTN in high-risk individuals.
Taking into account the advanced age of many participants in the PREDIMED trial and in some of the available cohorts, it can be concluded that it is never too late to improve the food pattern to improve CV health. Table 3 . Number of expected prevented cases with the PREDIMED primary prevention intervention for several hard clinical events (median follow-up: 4.8 years) in a hypothetical cohort of 1,000 subjects. Both Mediterranean diet groups were merged together.
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Clinical event
Number of prevented cases (95% CI) per 1,000 hypothetical participants receiving the PREDIMED MeDiet-intervention Primary CVD end-point 13 (4 to 20)
Type 2 diabetes 26 (7 to 41)
Peripheral artery disease 10 (6 to 13)
Atrial fibrillation 11 (2 to 18) Figure 1 . Baseline adherence to the Mediterranean diet (14-point PREDIMED score) and incidence of the primary end-point in the PREDIMED trial (a composite of myocardial infarction, stroke or cardiovascular death).
